x
BKS.Cg-Dock7m +/+ Leprdb/J mouse
Inquiryace

BKS.Cg-Dock7m +/+ Leprdb/J mouse

Inquiry

Cat. No.: DMM-001239

Status Age Sex
  • Live Mouse
  • Frozen Embryo
  • 4 weeks
  • 12 weeks
  • Customized Age
  • Male
  • Female
Model Overview
Model Description This strain is used to model phases I to III of diabetes type II and obesity. Mice homozygous for the diabetes spontaneous mutation (Leprdb) manifest morbid obesity, chronic hyperglycemia, pancreatic beta cell atrophy and become hypoinsulinemic. Obesity starts at 3 to 4 weeks of age. Elevated plasma insulin begins at 10 to 14 days and elevated blood sugar at 4 to 8 weeks. Homozygous mice are polyphagic, polydipsic, and polyuric. The severity of disease on BKS background leads to uncontrolled rise in blood sugar, severe depletion of insulin-producing beta-cells of the pancreatic islets, peripheral neuropathy, myocardial disease and death by 10 months of age. Exogenous insulin fails to control blood glucose levels and gluconeogenic enzyme activity increases. Wound healing is delayed, and metabolic efficiency is increased.
Background Strain C57BLKS/J
SPF Yes
Research Application Diabetes
Target Information
Target Name Lepr
Synonyms OBR, CD295, HuB219, LEP-R
Gene ID 3953
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
Related Models
logo

Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.

Quick Links
Contact Info
Copyright © Ace Therapeutics. All Rights Reserved.
Top